20.35
-0.02 (-0.10%)
| Penutupan Terdahulu | 20.37 |
| Buka | 19.86 |
| Jumlah Dagangan | 477,438 |
| Purata Dagangan (3B) | 796,393 |
| Modal Pasaran | 1,351,122,048 |
| Harga / Jualan (P/S) | 178.33 |
| Harga / Buku (P/B) | 1.92 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| Margin Operasi (TTM) | -9,027.19% |
| EPS Cair (TTM) | -2.70 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 345.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.49% |
| Nisbah Semasa (MRQ) | 21.67 |
| Aliran Tunai Operasi (OCF TTM) | -171.51 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -101.09 M |
| Pulangan Atas Aset (ROA TTM) | -16.88% |
| Pulangan Atas Ekuiti (ROE TTM) | -23.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Celldex Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 2.13 |
|
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.32% |
| % Dimiliki oleh Institusi | 113.13% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 64.00 (Canaccord Genuity, 214.50%) | Beli |
| Median | 43.00 (111.30%) | |
| Rendah | 31.00 (Goldman Sachs, 52.33%) | Pegang |
| Purata | 45.20 (122.11%) | |
| Jumlah | 4 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 19.34 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 16 Jun 2025 | 50.00 (145.70%) | Beli | 20.34 |
| 13 Jun 2025 | 50.00 (145.70%) | Beli | 21.26 | |
| Goldman Sachs | 09 May 2025 | 31.00 (52.33%) | Pegang | 18.33 |
| Morgan Stanley | 09 May 2025 | 43.00 (111.30%) | Beli | 18.33 |
| 20 Mar 2025 | 46.00 (126.04%) | Beli | 19.88 | |
| UBS | 09 May 2025 | 38.00 (86.73%) | Beli | 18.33 |
| Canaccord Genuity | 28 Apr 2025 | 64.00 (214.50%) | Beli | 21.36 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |